NMT Medical, AGA Medical settle
This article was originally published in The Gray Sheet
Executive Summary
In return for full and final settlement of NMT's 1999 patent infringement suit, AGA will pay NMT $30 mil. for a nonexclusive sublicense to patent '420, which relates to NMT's CardioSeal, the two firms announced March 28. The alleged infringement affects all AGA Amplatzer occluding devices. NMT will split the settlement with inventor Lloyd Marks, MD, according to the firm. NMT competes with AGA in the patent foramen ovale occlusion market with STARFlex. Preliminary results of NMT's MIST I trial suggest a connection between patent foramen ovale closure and migraine symptoms (1"The Gray Sheet" March 20, 2006, p. 3)...
You may also be interested in...
MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
Sanofi’s Dupixent Benefits In Chronic Spontaneous Urticaria Add To Strong Second Quarter
Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.
AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Bouyant Q2 Results
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.